Belzutifan tablets 40mg/tablet, 90 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Anemia: anemia is regularly monitored before and throughout treatment with LuciBelzu.
• Interrupt LuciBelzu until hemoglobin ≥ 8 g/dL and then resume or stop at the same or reduced dose. For life-threatening anemia, or anemia requiring urgent intervention, interrupt LuciBelzu until hemoglobin ≥ 8 g/dL and resume or permanently discontinue LuciBelzu with a reduced dose.
• Hypoxia: Pulse oximetry is regularly monitored prior to and throughout the start of LuciBelzu treatment. For hypoxia at rest, pause until remission, reduce dose recovery, or stop depending on severity. For life-threatening hypoxia, permanently discontinue LuciBelzu.

Medication risks

Adverse Reactions
VHL disease: The most common (≥ 25%) adverse reactions, including laboratory abnormalities, are hemoglobin decreased, fatigue, creatinine increased, headache, dizziness, blood sugar increased, and nausea.
Advanced renal cell carcinoma: The most common (≥ 25%) adverse reactions, including laboratory abnormalities, include decreased hemoglobin, fatigue, musculoskeletal pain, increased creatinine, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, and increased aspartate aminotransferase.